AU6011496A - Improved pharmaceutical compositions for gene therapy - Google Patents
Improved pharmaceutical compositions for gene therapyInfo
- Publication number
- AU6011496A AU6011496A AU60114/96A AU6011496A AU6011496A AU 6011496 A AU6011496 A AU 6011496A AU 60114/96 A AU60114/96 A AU 60114/96A AU 6011496 A AU6011496 A AU 6011496A AU 6011496 A AU6011496 A AU 6011496A
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutical compositions
- gene therapy
- improved pharmaceutical
- improved
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
- C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nanotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12495P | 1995-06-08 | 1995-06-08 | |
US000124 | 1995-06-08 | ||
GBGB9513399.7A GB9513399D0 (en) | 1995-06-30 | 1995-06-30 | Improved pharmaceutical compositions for gene therapy |
GB9513399 | 1995-06-30 | ||
GB9519304 | 1995-09-21 | ||
GBGB9519304.1A GB9519304D0 (en) | 1995-09-21 | 1995-09-21 | Improved pharmaceutical compositions for gene therapy |
US428595P | 1995-09-25 | 1995-09-25 | |
US004285 | 1995-09-25 | ||
US895295P | 1995-12-19 | 1995-12-19 | |
US008952 | 1995-12-19 | ||
GB9525955 | 1995-12-19 | ||
GBGB9525955.2A GB9525955D0 (en) | 1995-12-19 | 1995-12-19 | Improved pharmaceutical compositions |
US1153196P | 1996-02-12 | 1996-02-12 | |
US011531 | 1996-02-12 | ||
US66023196A | 1996-06-07 | 1996-06-07 | |
US660231 | 1996-06-07 | ||
PCT/GB1996/001396 WO1996041606A2 (en) | 1995-06-08 | 1996-06-10 | Improved pharmaceutical compositions for gene therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6011496A true AU6011496A (en) | 1997-01-09 |
Family
ID=27571323
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU60114/96A Abandoned AU6011496A (en) | 1995-06-08 | 1996-06-10 | Improved pharmaceutical compositions for gene therapy |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0831922A2 (en) |
JP (1) | JP2002514892A (en) |
AU (1) | AU6011496A (en) |
WO (1) | WO1996041606A2 (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6479464B1 (en) | 1997-05-21 | 2002-11-12 | Cobra Therapeutics Limited | Compositions and methods for highly efficient transfection |
US6689757B1 (en) | 1996-02-12 | 2004-02-10 | M.L. Laboratories Plc | Methods for vaccination and vaccines therefor |
ES2184990T3 (en) * | 1996-02-12 | 2003-04-16 | Ml Lab Plc | NEW VACCINATION METHODS AND VACCINES FOR THE SAME WHO UNDERSTAND A NUCLEIC ACID CODIFYING A FIRST EPITOPE AND A PEPTIDE CONTAINING A SECOND EPITOPE. |
US8007784B1 (en) | 1996-06-27 | 2011-08-30 | Albany Medical College | Antigenic modulation of cells |
DE69836746D1 (en) * | 1997-02-12 | 2007-02-08 | Innovata Plc Nottingham | COMPOSITIONS AND METHOD FOR HIGHLY EFFICIENT TRANSFECTION |
US5925628A (en) * | 1997-03-31 | 1999-07-20 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5912239A (en) * | 1997-04-04 | 1999-06-15 | Genzyme Corporation | Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules |
US5948925A (en) * | 1997-05-06 | 1999-09-07 | Genzyme Corporation | Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids |
US5952516A (en) * | 1997-05-08 | 1999-09-14 | Genzyme Corporation | Cationic amphiphiles containing multiplesteroid lipophilic groups |
US5942634A (en) * | 1997-05-09 | 1999-08-24 | Genzyme Corporation | Cationic amphiphiles for cell transfections |
AU7987898A (en) * | 1997-06-26 | 1999-01-19 | Albany Medical College | Antigenic modulation of viral particules |
AU2868099A (en) | 1998-02-13 | 1999-08-30 | Selective Genetics, Inc. | Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby |
WO1999042091A2 (en) * | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Use of polycations as endosomolytic agents |
WO2000005393A2 (en) | 1998-07-21 | 2000-02-03 | Cobra Therapeutics Limited | A polynucleotide comprising a ubiquitous chromatin opening element (ucoe) |
WO2000012114A1 (en) * | 1998-09-01 | 2000-03-09 | The Trustees Of The University Of Pennsylvania | Peptide scaffolds for transfer of molecules into eukaryotic cells |
US6927278B1 (en) | 1998-09-01 | 2005-08-09 | Trustees Of The University Of Pennsylvania | Peptide scaffolds for transfer of molecules into eukaryotic cells |
WO2000063409A1 (en) * | 1999-04-21 | 2000-10-26 | Massachusetts Institute Of Technology | Endosomolytic agents and cell delivery systems |
WO2000075162A1 (en) * | 1999-06-07 | 2000-12-14 | Mirus Corporation | A compound containing a labile disulfide bond |
DK1102785T3 (en) * | 1999-06-07 | 2013-05-13 | Arrowhead Res Corp | Compositions for drug delivery using pH-sensitive molecules |
GB9918670D0 (en) | 1999-08-06 | 1999-10-13 | Celltech Therapeutics Ltd | Biological product |
AU783128B2 (en) | 2000-03-02 | 2005-09-29 | Innovata Plc | TCF responsive element |
JP2004528266A (en) * | 2000-04-12 | 2004-09-16 | インプリクス リミテッド | Composition for drug delivery |
DE10114178A1 (en) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinc-free and low-zinc insulin preparations with improved stability |
DE10227232A1 (en) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Sour insulin preparations with improved stability |
JP5102630B2 (en) * | 2005-11-24 | 2012-12-19 | ジェノミディア株式会社 | Modified paramyxovirus and method for producing the same |
KR101939557B1 (en) | 2008-10-17 | 2019-01-17 | 사노피-아벤티스 도이칠란트 게엠베하 | Combination of an insulin and a GLP-1 agonist |
PT3345593T (en) | 2009-11-13 | 2023-11-27 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising despro36exendin-4(1-39)-lys6-nh2 and methionine |
CN107308442B (en) | 2009-11-13 | 2022-10-18 | 赛诺菲-安万特德国有限公司 | Pharmaceutical composition comprising a GLP-1 agonist, insulin and methionine |
EA023927B1 (en) | 2010-06-22 | 2016-07-29 | Дна Терапьютикс | Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates |
LT2611458T (en) | 2010-08-30 | 2016-12-27 | Sanofi-Aventis Deutschland Gmbh | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
MX370264B (en) | 2011-08-29 | 2019-12-09 | Sanofi Aventis Deutschland | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients. |
AR087744A1 (en) | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE |
SI3229828T1 (en) | 2014-12-12 | 2023-06-30 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
TWI748945B (en) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | Treatment type 2 diabetes mellitus patients |
TW201705975A (en) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | Treatment of type 2 diabetes mellitus patients |
KR101896567B1 (en) | 2015-07-23 | 2018-09-07 | 인스티튜트 큐리 | Combined use of deblock molecule and PARP inhibitor for cancer treatment |
WO2018096457A1 (en) * | 2016-11-22 | 2018-05-31 | Kabushiki Kaisha Toshiba | Nucleic acid condensing peptide, nucleic acid condensing peptide set, nucleic acid delivery carrier, nucleic acid delivery method, cell production method, cell detection method and kit |
WO2018227231A1 (en) * | 2017-06-13 | 2018-12-20 | Monash University | Non-viral gene delivery agent comprising lipopeptide (lp) compounds |
WO2020097235A1 (en) * | 2018-11-08 | 2020-05-14 | Summation Bio, Inc. | Mini-nucleosome core proteins and use in nucleic acid delivery |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4139001A1 (en) * | 1991-11-27 | 1993-06-03 | Boehringer Mannheim Gmbh | PROCESS FOR INJECTION OF NUCLEAR ACIDS IN CELLS |
ES2221920T3 (en) * | 1992-04-03 | 2005-01-16 | The Regents Of The University Of California | SELF-ASSEMBLY POLYUCLEOTID RELEASE SYSTEM THAT INCLUDES AN AMPHIPATIC CATIONIC PEPTIDE. |
DE4412629A1 (en) * | 1993-04-14 | 1995-01-26 | Boehringer Mannheim Gmbh | Nucleic acid transfer peptides and their use for including nucleic acids in eucaryotic cells |
AU7634694A (en) * | 1993-08-20 | 1995-03-21 | University Of Medicine And Dentistry Of New Jersey | Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same |
FR2715847B1 (en) * | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition containing nucleic acids, preparation and uses. |
GB9425600D0 (en) * | 1994-12-19 | 1995-02-15 | Medical Res Council | Targeting complexes and use thereof |
FR2730637B1 (en) * | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | PHARMACEUTICAL COMPOSITION CONTAINING NUCLEIC ACIDS, AND USES THEREOF |
-
1996
- 1996-06-10 EP EP96917590A patent/EP0831922A2/en not_active Withdrawn
- 1996-06-10 WO PCT/GB1996/001396 patent/WO1996041606A2/en not_active Application Discontinuation
- 1996-06-10 JP JP50279197A patent/JP2002514892A/en active Pending
- 1996-06-10 AU AU60114/96A patent/AU6011496A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1996041606A2 (en) | 1996-12-27 |
JP2002514892A (en) | 2002-05-21 |
EP0831922A2 (en) | 1998-04-01 |
WO1996041606A3 (en) | 1997-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU6011496A (en) | Improved pharmaceutical compositions for gene therapy | |
AU6216296A (en) | Pharmaceutical compositions | |
AU7572196A (en) | Pharmaceutical formulations | |
AU6995396A (en) | Pharmaceutical formulation | |
AU5402296A (en) | Pharmaceutical composition for transdermic administration | |
AUPN605795A0 (en) | Analgesic pharmaceutical composition | |
AU4787697A (en) | Therapeutic gene | |
AUPN411195A0 (en) | Medicinal composition | |
AU6740298A (en) | Pharmaceutical composition | |
AU7590096A (en) | Drug composition | |
AU6973396A (en) | Pharmaceutical formulation | |
AU6904896A (en) | Pharmaceutical compounds | |
AU8107998A (en) | Pharmaceutical compositions | |
AU5155096A (en) | Pharmaceutical composition | |
AU5274096A (en) | Pharmaceutical compositions | |
AU2531295A (en) | Pharmaceutical composition | |
AU7582696A (en) | Pharmaceutical formulation | |
AU9343098A (en) | Pharmaceutical composition | |
AU4417000A (en) | Novel pharmaceutical composition suitable for gene therapy | |
AU1172097A (en) | Pharmaceutical composition containing trehalose | |
AUPN727595A0 (en) | Therapeutic compositions | |
AU7546096A (en) | Pharmaceutical compounds | |
AU4712296A (en) | Pharmaceutical preparations for TNF inhibition | |
AU1427895A (en) | Pharmaceutical compositions | |
AU1544195A (en) | Pharmaceutical compositions |